See post replying... Stock showing some life...from the speculation list...
Birmingham, West Midlands – July 08, 2014– (TechSonian) –Prana Biotechnology Limited (ADR) (PRAN)researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It mostly focuses on the Alzheimer’s, Parkinson’s, and Huntington’s diseases, as well as various cancer and age-related macular degeneration. The company’s product line includes PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer’s disease, as well as in Phase IIa clinical trials to treat Huntington’s disease.
An approved Alzheimer's drug for disease modification will generate at least $5 billion a year in revenue on average, as no drugs currently exist. LMTX from TauRx, Crenezumab from Roche, and PBT2 from Prana are best-positioned to succeed; PBT2 has the best overall position. Prana's previous trials have been unimpressive, but hidden inside those results are clues to a highly-effective drug. Prana stock is significantly undervalued, but is unlikely to remain so after releasing Phase IIb Alzheimer's results later this month. There are few diseases as widespread and debilitating as Alzheimer's disease. It is one of the few diseases that has really stumped modern medicine, as the overall prognosis of someone with Alzheimer's disease today is not that much different from someone 50 years ago. Granted, knowledge of the disease has drastically improved over the years, but there are no disease-modifying treatments on the market today to slow or stop the progression of the disease
News 
Market Data 
Discover 
